Patricia Alice Shaw
#56,574
Most Influential Person Now
Canadian linguist
Patricia Alice Shaw's AcademicInfluence.com Rankings
Patricia Alice Shawcommunications Degrees
Communications
#1783
World Rank
#2629
Historical Rank
Linguistics
#525
World Rank
#684
Historical Rank
Download Badge
Communications
Why Is Patricia Alice Shaw Influential?
(Suggest an Edit or Addition)According to Wikipedia, Patricia Alice Shaw is a Canadian linguist specializing in phonology and known for her work on First Nations languages. Education and career Patricia Shaw was born in Montreal and moved at the age of 12 to Winnipeg. She received her B.A. in English from St. John's College of the University of Manitoba in 1967, her M.A. in Linguistics from the University of Toronto in 1973, and her Ph.D. in Linguistics from the University of Toronto in 1976 with a dissertation on Theoretical Issues in Dakota Phonology and Morphology.
Patricia Alice Shaw's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- International network of cancer genome projects (2010) (1839)
- Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes (2012) (1752)
- Cancer classification using the Immunoscore: a worldwide task force (2012) (719)
- Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. (2006) (666)
- Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. (2006) (377)
- Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. (2011) (371)
- How important is removal of the parametrium at surgery for carcinoma of the cervix? (2002) (284)
- Is radical trachelectomy a safe alternative to radical hysterectomy for patients with Stage IA–B carcinoma of the cervix? (1999) (222)
- Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells (2011) (219)
- Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers (2009) (196)
- Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. (2012) (196)
- Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial (2016) (188)
- Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas (2013) (182)
- Cancer genomics: technology, discovery, and translation. (2012) (181)
- A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers. (2008) (153)
- Gene Expression Profiles of Luteal Phase Fallopian Tube Epithelium from BRCA Mutation Carriers Resemble High-Grade Serous Carcinoma (2008) (152)
- Diagnosis of Serous Tubal Intraepithelial Carcinoma Based on Morphologic and Immunohistochemical Features: A Reproducibility Study (2011) (145)
- Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma (2017) (133)
- Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2. (2013) (128)
- Validation of an Algorithm for the Diagnosis of Serous Tubal Intraepithelial Carcinoma (2012) (122)
- Histopathologic Features of Genetically Determined Ovarian Cancer (2002) (120)
- A distinct innate lymphoid cell population regulates tumor-associated T cells (2017) (117)
- Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy (2016) (115)
- Changes in the demographics and perioperative care of stage IA(2)/IB(1) cervical cancer over the past 16 years. (2001) (111)
- Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus–Related Cervical Carcinoma (2017) (108)
- High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer. (2005) (101)
- The Histomorphology of Lynch Syndrome–associated Ovarian Carcinomas: Toward a Subtype-specific Screening Strategy (2014) (96)
- Epithelial-stromal interaction increases cell proliferation, survival and tumorigenicity in a mouse model of human epithelial ovarian cancer. (2008) (93)
- Feasibility of real time next generation sequencing of cancer genes linked to drug response: Results from a clinical trial (2013) (86)
- DICER1 Mutations Are Consistently Present in Moderately and Poorly Differentiated Sertoli-Leydig Cell Tumors (2017) (83)
- Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy (2014) (79)
- Kinesin family member 14: An independent prognostic marker and potential therapeutic target for ovarian cancer (2012) (77)
- Does histology influence prognosis in patients with early‐stage cervical carcinoma? (2001) (76)
- In-depth proteomics of ovarian cancer ascites: combining shotgun proteomics and selected reaction monitoring mass spectrometry. (2011) (75)
- Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. (2017) (71)
- Frequency of mutations in mismatch repair genes in a population-based study of women with ovarian cancer (2012) (71)
- A phase II study of leuprolide in advanced/recurrent endometrial cancer. (1997) (70)
- Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors (2018) (67)
- Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study (2014) (65)
- Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary. (2010) (64)
- BRCA and Early Events in the Development of Serous Ovarian Cancer (2013) (64)
- Regulatory T Cells in Ovarian Cancer Are Characterized by a Highly Activated Phenotype Distinct from that in Melanoma (2018) (59)
- Histopathologic score predicts recurrence free survival after radical surgery in patients with stage IA2–IB1–2 cervical carcinoma (2003) (54)
- Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach. (2017) (54)
- Differences in the morbidity of radical hysterectomy between gynecological oncologists. (1993) (52)
- Expansion and Characterization of Human Melanoma Tumor-Infiltrating Lymphocytes (TILs) (2010) (50)
- Loss of SMARCA4 (BRG1) protein expression as determined by immunohistochemistry in small‐cell carcinoma of the ovary, hypercalcaemic type distinguishes these tumours from their mimics (2016) (46)
- Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations. (1999) (46)
- Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression (2007) (45)
- Endometrial sarcomas: an immunohistochemical and JAZF1 re-arrangement study in low-grade and undifferentiated tumors (2013) (43)
- High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation (2019) (41)
- Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study (2018) (40)
- Novel EPC1 gene fusions in endometrial stromal sarcoma (2018) (39)
- Identification of abrogated pathways in fallopian tube epithelium from BRCA1 mutation carriers (2011) (38)
- International Society of Gynecological Pathologists (ISGyP) Endometrial Cancer Project: Guidelines From the Special Techniques and Ancillary Studies Group (2018) (36)
- A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium (2018) (36)
- Proliferation in the Normal FTE Is a Hallmark of the Follicular Phase, Not BRCA Mutation Status (2012) (36)
- Specimen quality evaluation in Canadian biobanks participating in the COEUR repository. (2013) (36)
- Retinoblastoma pathway deregulatory mechanisms determine clinical outcome in high-grade serous ovarian carcinoma (2014) (36)
- Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap (2018) (32)
- Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC). (2017) (32)
- Molecular evidence for putative tumour suppressor genes on chromosome 13q specific to BRCA1 related ovarian and fallopian tube cancer (2002) (32)
- Interstitial permeability and elasticity in human cervix cancer. (2008) (28)
- Loss of LKB1 and p53 synergizes to alter fallopian tube epithelial phenotype and high-grade serous tumorigenesis (2016) (28)
- Risk factors for non-invasive lesions of the fallopian tube in BRCA mutation carriers. (2010) (28)
- Prolonged postovulatory proinflammatory signaling in the fallopian tube epithelium may be mediated through a BRCA1/DAB2 axis. (2012) (27)
- Review of findings in prophylactic gynaecological specimens in Lynch syndrome with literature review and recommendations for grossing (2014) (26)
- TP53 mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analyses (2019) (26)
- Prognostic factors for relapse and pelvic lymph node metastases in early stage I adenocarcinoma of the cervix. (1999) (25)
- Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer. (2015) (24)
- Correlation between germline mutations in MMR genes and microsatellite instability in ovarian cancer specimens (2017) (24)
- A Genomically Characterized Collection of High-Grade Serous Ovarian Cancer Xenografts for Preclinical Testing. (2018) (23)
- Differences between hereditary and sporadic ovarian cancer. (1999) (20)
- Decreased progesterone receptor isoform expression in luteal phase fallopian tube epithelium and high-grade serous carcinoma (2011) (20)
- Tumor cell expression of B7-H4 correlates with higher frequencies of tumor-infiltrating APCs and higher CXCL17 expression in human epithelial ovarian cancer (2019) (18)
- IL6 Induces an IL22+ CD8+ T-cell Subset with Potent Antitumor Function (2020) (17)
- Chromosomal instability and mTORC1 activation through PTEN loss contribute to proteotoxic stress in ovarian carcinoma. (2019) (15)
- Implementing a Cervical Sentinel Lymph Node Biopsy Program: Quality Improvement in Gynaecologic Oncology. (2017) (11)
- The role of KIF14 in patient-derived primary cultures of high-grade serous ovarian cancer cells (2014) (10)
- In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose. (2015) (9)
- Integrative Transcriptome Analyses of the Human Fallopian Tube: Fimbria and Ampulla—Site of Origin of Serous Carcinoma of the Ovary (2020) (9)
- Genomic profiling identifies GPC5 amplification in association with sarcomatous transformation in a subset of uterine carcinosarcomas (2018) (8)
- CCAAT/enhancer binding protein delta (C/EBPδ) demonstrates a dichotomous role in tumour initiation and promotion of epithelial carcinoma (2019) (8)
- Analysis of outcomes in patients (pts) with recurrent ovarian clear cell carcinoma (ROCCC): Time to rethink our approach to treatment. (2014) (7)
- Letter to the editor regarding ‘Roh MH, Lassin Y, Miron A et al. High-grade fimbrial-ovarian carcinomas are unified by p53, PTEN and PAX2 expression’ (2011) (7)
- Phase II clinical and molecular trial of oral ENMD-2076 in clear cell ovarian cancer (CCOC): A study of the Princess Margaret phase II consortium. (2017) (6)
- Heterogeneous alteration of the ERBB3–MYC axis associated with MEK inhibitor resistance in a KRAS-mutated low-grade serous ovarian cancer patient (2019) (6)
- Cancer precursor lesions in the BRCA population at the time of prophylactic salpingo-oophorectomy: Accuracy of assessment and potential surrogate marker for prevention. (2015) (6)
- Prophylactic Gynecologic Specimens from Hereditary Cancer Carriers. (2016) (5)
- Accumulation of p 53 protein is frequent in ovarian cancers associated with BRCA 1 and BRCA 2 germline mutations (1999) (5)
- Incidental MRI detection of BRCA1-related solitary peritoneal carcinoma during breast screening--A case report. (2007) (5)
- Survival in women with ovarian cancer with and without microsatellite instability. (2015) (4)
- Phase II open-label randomized multi-centre study of neoadjuvant olaparib in patients (pts) with platinum sensitive (PS) relapsed high grade serous ovarian cancer (OC): The NEO trial. (2017) (3)
- Abstract B48: Feasibility study of molecular profiling (MP) in patients (Pts) with advanced solid cancers using targeted mutation analysis and targeted exome sequencing. (2011) (3)
- Prolonged Postovulatory Proin fl ammatory Signaling in the Fallopian Tube Epithelium May Be Mediated through a BRCA 1 / DAB 2 Axis (2012) (3)
- Avoidance of apoptotic death via a hyperploid salvage survival pathway after platinum treatment in high grade serous carcinoma cell line models (2019) (2)
- How important is removal of the parametrium at surgery for carcinoma of the cervix (2002) (2)
- Leuprolide in the treatment of endometrial cancer (multiple letters) (1997) (2)
- Antioxidant gene expression program is deregulated early in serous ovarian cancer (2017) (1)
- Hereditary Carcinomas of the Ovary, Fallopian Tube, and Peritoneum. (2011) (1)
- Precursors of High-Grade Serous Carcinoma (2016) (1)
- Abstract 1454: Estrogen receptor signaling in FTE of BRCA mutation carriers (2017) (1)
- 878PDBENEFICIAL EFFECT OF ADJUVANT CHEMOTHERAPY AND WHOLE ABDOMINAL OR PELVIC RADIOTHERAPY (WAPRT) ON PROGRESSION FREE AND OVERALL SURVIVAL FOLLOWING PRIMARY SURGERY IN PATIENTS WITH OVARIAN CLEAR CELL CARCINOMA (OCCC). (2014) (1)
- The Prevent Ovarian Cancer Program (POCP): Identification of women at risk for ovarian cancer using complementary recruitment approaches. (2021) (1)
- Abstract A186: KIF14 is a novel therapeutic target for ovarian cancer. (2011) (1)
- Genotype matched treatment for patients with advanced type I epithelial ovarian cancer (EOC). (2014) (1)
- Abstract #181: Identification and characterization of serous ovarian cancer-initiating cells (2009) (1)
- Cancer classification using the Immunoscore: a worldwide task force (2012) (1)
- Abstract 2835: BRCA1 signature in high-risk fallopian tube epithelium (2011) (0)
- Abstract 2080: Differential transcription profile of epithelia in fimbria versus the ampulla of the fallopian tube (2015) (0)
- Characterization of low grade serous carcinoma of the ovary and its precursorss (2007) (0)
- Abstract A63: Estrogen receptor signaling in fallopian tube epithelia of BRCA mutation carriers (2018) (0)
- C/EBPδ demonstrates a dichotomous role in tumor initiation and promotion of epithelial carcinoma (2019) (0)
- High-Resolution Mapping of Genomic Imbalance and Identification of Gene Expression Profiles Associated with Differential Chemotherapy Response in Serous Epithelial Ovarian Cancer 1 * (2005) (0)
- Abstract A27: Transcriptome analyses of human ampulla and fimbriae highlight similarities and differences. (2016) (0)
- Abstract DP-005: RNA-SEQUENCING OF FALLOPIAN TUBE – FIMBRIA AND HGSC FROM BRCA MUTATION CARRIERS (2019) (0)
- Abstract SY35-02: Phenotypic heterogeneity and instability of human serous ovarian cancer tumor-initiating cells (2012) (0)
- PP 2 Generation of a panel of “actionable” cancer genes for molecular profiling (MP) in a feasibility study of targeted and genome wide sequencing (TGWS) (2011) (0)
- Abstract A11: Loss of LKB1 is an early event in high-grade serous carcinoma (2011) (0)
- Abstract A9: The pancreatic ductal adenocarcinoma project at the Ontario Institute for Cancer Research. (2012) (0)
- Somatic mutation profiling of advanced breast and ovarian cancers according to germline BRCA1/2 mutation status. (2015) (0)
- Abstract 4303: Definitive identification and characterization of ovarian cancer-initiating cells (2010) (0)
- Abstract 3318: Phenotypic heterogeneity and instability of tumor-initiating cells in high-grade serous cancer (2012) (0)
- Abstract B91: Primary tumor xenograft establishment from pancreatic resection specimens. (2012) (0)
- Abstract 3068: Proteotoxic stress associated with mTORC1 activation in ovarian carcinoma: proteasome inhibition as a therapeutic strategy (2017) (0)
- Abstract LB-230: A prospective clinical trial to evaluate DNA sequencing as a diagnostic tool to guide cancer therapy: results from the initial 50 patients (2012) (0)
- Sertoli-Leydig Cell Tumors: Examination of Morphologic Features and Correlation with Germline and Somatic DICER 1 Mutation (2017) (0)
- Abstract 4765: The role of estrogen receptor signalling in serous ovarian cancer. (2013) (0)
- Hormonal receptor expression and clinical outcome in ovarian high-grade serous carcinoma (2019) (0)
- LEUPROLIDE IN THE TREATMENT OF ENDOMETRIAL CANCER. AUTHORS' REPLY (1997) (0)
- Abstract A82: Ovarian cancer cells hijack immune functions of omental milky spots for metastatic colonization. (2016) (0)
- Molecular profiling and targeted therapy in advanced endometrial cancer. (2015) (0)
- Abstract B29: Ovarian hormones regulate C/EBPD induced EMT/MET transition in the human fallopian tube epithelia (2020) (0)
- C/EBPδ demonstrates dichotomous tumor initiation and promotion in high grade serous ovarian carcinogenesis (2019) (0)
- Germline and somatic homologous recombination gene mutations in high-grade serous ovarian cancer and clinical outcome. (2016) (0)
- The Fallopian Tube as a Primary Origin of Serious Ovarian Cancers. (2012) (0)
- Abstract A35: Elucidating mechanisms involved in long-term response to platinum-based chemotherapy in high-grade serous ovarian cancer. (2016) (0)
- GENOMIC AND TRANSCRIPTOME PROFILING OF EPITHELIAL OVARIAN CANCER (2008) (0)
- Androgen-Induced Altered Gene Expression Profiles in Ovarian Epithelial Cells From BRCA1 and 2 Mutation Carriers as Compared to Cells From Control Patients (2005) (0)
- Identification of antigenic epitopes recognized by tumor infiltrating lymphocytes in high grade serous ovarian cancer by multi-omics profiling of the auto-antigen repertoire. (2023) (0)
- Abstract B12: Differences in neoplastic transformation potential between OSE and FTE (2018) (0)
- Abstract 02: Pan-cancer analysis of hotspot mutations in genes encoding the members of mitogen activated protein kinase (MAPK) and phosphoinosidtide-3 kinase (PI3K) pathways among smokers and non-smokers (2016) (0)
- The prevent ovarian cancer program (POCP): Identification of ovarian cancer-associated mutations in self-referring women from low-risk families (2019) (0)
- COMPARATIVE GENE EXPRESSION BETWEEN BRCA-DEPENDENT AND SPORADIC SEROUS OVARIAN CANCER: IS THE DNA REPAIR PATHWAY A COMMON LINK? (2004) (0)
- Prospective validation of sentinel lymph node (SLN) biopsy with indocyanine green (ICG) fluorescence imaging in high-risk endometrial cancer (2018) (0)
- P53 functional mutation type in high-grade serous ovarian cancer and clinical outcomes. (2016) (0)
- The Prevent Ovarian Cancer Program (POCP): Identification of Women at Risk for Ovarian Cancer Using Complementary Recruitment Approaches (2021) (0)
- Abstract 333: The role of the retinoblastoma pathway (Rb) in high grade serous ovarian varcinoma (HGSC) (2011) (0)
- Integrated genomic analysis of STIC-associated high-grade serous carcinoma (2015) (0)
- Antitumor activity, safety and predictive biomarker results of ENMD-2076 administered to patients (pts) with recurrent ovarian clear cell carcinoma (OCCC): A trial of the Princess Margaret Phase II Consortium. (2016) (0)
- Correlation between germline mutations in MMR genes and microsatellite instability in ovarian cancer specimens (2017) (0)
- Abstract PL03-01: Origins of ovarian cancer, the biology of premalignancy, and cancer health disparities (2014) (0)
- Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors (2018) (0)
- Abstract POSTER-BIOL-1312: The role of BRCA and CEBPD in serous ovarian cancer carcinogenesis (2015) (0)
- Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial (2016) (0)
- long- t erm Ov arian cancer Sur vival Associated With Mutation in Brc A1 or B rc A2 (2012) (0)
- A phase Ib trial of pembrolizumab (Pembro) following adoptive cell therapy (ACT) in patients with platinum-resistant ovarian cancer; The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) trial. (2018) (0)
This paper list is powered by the following services:
Other Resources About Patricia Alice Shaw
What Schools Are Affiliated With Patricia Alice Shaw?
Patricia Alice Shaw is affiliated with the following schools:
